Patents
Literature
157 results about "Open reading frame" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In molecular genetics, an open reading frame (ORF) is the part of a reading frame that has the ability to be translated. An ORF is a continuous stretch of codons that begins with a start codon (usually AUG) and ends at a stop codon (usually UAA, UAG or UGA). An ATG codon (AUG in terms of RNA) within the ORF (not necessarily the first) may indicate where translation starts. The transcription termination site is located after the ORF, beyond the translation stop codon. If transcription were to cease before the stop codon, an incomplete protein would be made during translation. In eukaryotic genes with multiple exons, introns are removed and exons are then joined together after transcription to yield the final mRNA for protein translation. In the context of gene finding, the start-stop definition of an ORF therefore only applies to spliced mRNAs, not genomic DNA, since introns may contain stop codons and/or cause shifts between reading frames. An alternative definition says that an ORF is a sequence that has a length divisible by three and is bounded by stop codons. This more general definition can also be useful in the context of transcriptomics and/or metagenomics, where start and/or stop codon may not be present in the obtained sequences. Such an ORF corresponds to parts of a gene rather than the complete gene.
Synthetic non-coding RNAS
Synthetic RNA molecules comprising at least two RNA-binding protein (RBP)-binding motifs, wherein the at least two RBP-binding motifs bind the same first RBP and comprise non-identical sequences are provided. Synthetic RNA molecules comprising an RBP-binding motif that binds two orthogonal RBPs, comprising at least three RBP-binding motifs for three orthogonal RBPs or comprising a first RBP-binding motif, a second RBP-binding motif, a regulatory element and an open reading frame wherein the first and second RBP-binding motifs cooperatively enhance translation of the open reading frame are also provided. Compositions, cells and methods of use or generating the synthetic RNA molecules are also provided.
Owner:TECHNION RES & DEV FOUND LTD
Modified PIV5 vaccine vectors: methods of making and using
A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.
Owner:SIANBACK LLC
TREM for use in correction of missense mutations
The present invention generally relates to tRNA-based effector molecules for use in inserting missense mutations into the open reading frame (ORF) of a gene, e.g., for the treatment of repetitive sequence amplification diseases.
Owner:FLAGSHIP PIONEERING INNOVATIONS VI LLC
Single-chain and double-protein expressed circular RNA (Ribonucleic Acid) construct as well as preparation method and application thereof
The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.
Owner:DONGHUA UNIV
Dengue and / or zika virus genetically engineered vaccine and preparation method and application thereof
This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES
Pharmaceutical composition for treating cancer
PCT designated stageWO2026127065A1Organic active ingredientsGenetic material ingredientsOpen reading framePharmacy medicine
The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.
Owner:NAT UNIV ASAHIKAWA MEDICAL UNIV +1
Messenger RNA with heterologous untranslated regions for enhanced expression and uses thereof
Disclosed herein are a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a protein of interest, a heterologous 5' untranslated region (UTR) and / or a heterologous 3' UTR for highly expressing the protein of interest. A method for synthesizing the mRNA and uses of the mRNA are also provided.
Owner:DEV CENT FOR BIOTECHNOLOGY +1
Replication-deficient influenza virus vaccine skeleton, replication-deficient influenza virus and application
PendingCN121852337Aincrease capacitySsRNA viruses negative-senseViral antigen ingredientsAntigenOpen reading frame
The invention relates to the field of biology, and particularly provides a replication-deficient influenza virus vaccine skeleton which comprises a PA gene, an HA gene, an NP gene, an NA gene, an M gene, an NS gene and a PB2 gene of an influenza virus. The PB2 gene is replaced into a PB1 gene coding region of a vaccine skeleton; the open reading frame of the original PB2 gene can be replaced by an exogenous gene, so that the exogenous gene is inserted into the vaccine skeleton and expressed. The skeleton has the advantages that the capacity is large, the antigen can be efficiently and stably expressed, the passage is stable, and the like. Meanwhile, the invention also discloses a replication-defective influenza virus as well as a preparation method and application thereof.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +3
Ultrasensitive assays for detection of ORF1p in biofluids
PendingUS20260176701A1Microbiological testing/measurementImmunoglobulinsOpen reading frameBioinformatics
Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +4
Food-borne pathogenic bacterium typing method based on wgMLST technology
The invention relates to the technical field of bioinformatics and microbial genome analysis, in particular to a food-borne pathogenic bacterium typing method based on a wgMLST technology, which comprises the following steps of: preliminarily comparing a genome sequence with a constructed lightweight wgMLST database, and aiming at imperfectly matched gene loci in a comparison result, identifying the genomic sequence in the lightweight wgMLST database and identifying the genomic sequence in the lightweight wgMLST database. And expanding or cutting off the sequence according to the comparison region, predicting and extracting a potential open reading frame (ORF) sequence, and carrying out dictionary comparison on the potential ORF sequence until matching succeeds, thereby accurately judging the corresponding number of the allele. And traversing all imperfect matching sites and repeating the process to finally obtain a complete wgMLST typing spectrum. According to the method, a wgMLST typing task of large-scale high-throughput sequencing data can be efficiently processed; the complete analysis speed of single pathogenic bacteria is increased by nearly 10 times; a complete allele dictionary is introduced for secondary comparison and error correction, and it is ensured that imperfect matching site typing is correct and high in accuracy; and a technical support is provided for high-throughput strain detection and typing.
Owner:CHINA AGRI UNIV +1
Regulator of chromosome 9 open reading frame 72 gene expression and application thereof
PendingCN120960394AOrganic active ingredientsFusion with DNA-binding domainOpen reading frameMedicine
The present disclosure provides compositions and methods for modulating C9orf72 gene transcription in patients in need thereof, including patients suffering from C9orf72 related diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Owner:SANGAMO THERAPEUTICS INC
Antioxidant-producing strain
The present invention refers to a composition comprising Cutibacterium acnes (C. acnes) bacterial strains, wherein said strains are characterized by being modified to secrete a heterologous protein by insertion of an expression construct comprising at least one or more transcription promoter sequences, one or more ORFs (Open Reading Frames) encoding the heterologous protein, and one or more transcription termination sequences; wherein the heterologous protein is characterized by comprising at the N-terminus of the protein sequence, a secretion signal which is processed by C. acnes to secrete the protein, and wherein the heterologous protein is the superoxide dismutase enzyme.
Owner:UNIV POMPEU FABRA +1
Poly mRNA
PCT designated stageWO2026052111A1Antibody medical ingredientsDNA/RNA fragmentationOpen reading frameBiochemistry
Provided is a poly mRNA, comprising a plurality of mRNA structures. Each mRNA structure comprises: a cap region at the 5' end; and an open reading frame (ORF) encoding a polypeptide. The plurality of mRNA structures comprise a first mRNA structure and a second mRNA structure. The 3' terminus of the first mRNA structure is covalently linked to the second mRNA structure.
Owner:PIXEL BIOSCIENCES (SUZHOU) CO LTD
Organ fibrosis-related micropeptide ofmp and application thereof
This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Pseudosciaena crocea IRE1 alpha protein polyclonal antibody as well as preparation method and application thereof
The invention relates to the technical field of genetic engineering, in particular to a small yellow croaker IRE1 alpha protein polyclonal antibody as well as a preparation method and application thereof. The invention provides a preparation method of a small yellow croaker IRE1alpha protein polyclonal antibody. The preparation method comprises the following steps: cloning an open reading frame of a small yellow croaker IRE1alpha gene, and constructing a small yellow croaker IRE1alpha gene recombinant expression vector pET-30a (+)-IRE1alpha. Performing inducible expression and purification on the recombinant protein of the Larimichthys polyactis IRE1 alpha, and performing specific analysis on Western Blot; and preparing the polyclonal antibody of the small yellow croaker IRE1 alpha. According to the invention, a recombinant expression vector of the small yellow croaker IRE1alpha gene is constructed by adopting molecular biology and genetic engineering methods, purified recombinant protein is obtained through induced expression and affinity chromatography, the prepared polyclonal antibody can be used for expression detection of the small yellow croaker IRE1alpha protein, and an important material foundation is laid for research on functions and action mechanisms of the small yellow croaker IRE1alpha protein.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
Method for high-throughput identification of lncrna-encoded peptides and application thereof
The application relates to a high-throughput identification method of lncRNA coding peptides and application thereof, and belongs to the technical field of biology. The method combines a translationomics technology and a protein mass spectrometry technology, takes ribosome footprint sequencing data as a starting point, determines an open reading frame located on an lncRNA gene according to a three-base periodicity rule of a sequencing fragment, further constructs a proteogenomics index after systematic filtration, uses a computational proteomics method to detect an lncRNA translation event, and systematically identifies lncRNA coding peptides on the basis. The method has the characteristics of modularity and strong expandability, can be widely used for various types of proteome data, and can high-throughput identify and quantitatively detect lncRNA coding peptides. The application provides a prediction of molecular typing and prognosis of cancer patients based on an lncRNA coding peptide network model, and provides an important reference basis for precise medication of clinical patients.
Owner:SHENYANG PHARMA UNIV
A micropeptide, nucleic acids encoding the same and use in modulating microglial inflammatory activation
This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.
Owner:SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL
MRNA vaccines encoding EBV antigen proteins and uses thereof
The invention discloses a nucleic acid molecule which comprises an open reading frame for coding an EBV antigen, and the EBV antigen is a specific antigen which is contained in a diseased cell of an EBV related disease, is coded by an EBV virus genome and is in a cell and on a cell membrane; the EBV antigen comprises LMP1, LMP2A, LMP2B, EBNA-LP, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA4, EBNA5, EBNA6, EBNA7 and EBNA8, as well as lipid nanoparticles containing nucleic acid molecules, a pharmaceutical composition and application thereof, and belongs to the technical field of biology. The nucleic acid molecule, the mRNA, the composition containing the nucleic acid molecule, and the lipid nanoparticles can significantly increase the number of tumor specific immune cells, effectively activate immune response, and significantly inhibit tumor growth, and have significant anti-tumor activity for nasopharynx cancer and lymphoma.
Owner:WESTGENE BIOPHARMA CO LTD
Self-replicating RNA and use thereof
The present application relates to a replicable RNA molecule and the use thereof. The replicable RNA molecule comprises, from the 5′ end to the 3′ end, a 5′ cap, a 5′ UTR, an open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3′ UTR and a poly(A) tail, wherein the RNA replicase is capable of amplifying the replicable RNA molecule and is capable of amplifying an RNA molecule containing the sequence of interest and 3′ UTR, wherein the RNA replicase is a nonstructural protein or a functional variant thereof derived from Mosso das Pedras virus (MDPV), Everglades virus (EVEV), Rio Negro virus (RNV), Mucambo virus (MUCV), Highlands J virus (HJV), Pixuna virus (PIXV), Trocara virus (TROV), Cabassou virus (CABV), Tonate virus (TONV), Bebaru virus (BEBV), Fort Morgan virus (FMV), Getah virus (GETV) or Ndumu virus (NDUV).
Owner:NANJING GENSCRIPT BIOTECH CO LTD
Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes
PCT designated stageWO2025245495A1Peptide/protein ingredientsGenetic material ingredientsCancer cellOpen reading frame
The present disclosure provides cancer cells that have been specifically sensitized to enhance their elimination by cytotoxic lymphocytes. The sensitized cancer cells, in some examples, overexpress one or more newly identified cytotoxic-lymphocyte sensitizing proteins, where the overexpression is achieved with, for example, a guide-based gene activation system, or transformation of the cancer cells with an open reading frame encoding the cytotoxic-lymphocyte sensitizing protein. The disclosure further provides cytotoxic lymphocytes engineered to overexpress antitumor enhancing ligands that act in a paracrine signaling mechanism to induce increased cytotoxic activity for the engineered lymphocytes. Also provided are methods for producing the sensitized cancer cells and engineered cytotoxic lymphocytes, and methods for treating or preventing a cancer.
Owner:CZ BIOHUB SF LLC +1
Engineered murine cytomegalovirus-derived tool virus, method of producing the same and applications thereof
PendingUS20250361526A1Compounds screening/testingAntibody mimetics/scaffoldsOpen reading frameEngineered genetic
A tool virus derived from genetically engineered MCMV K181 strain for tracing MCMV infection, wherein the tool virus is a recombinant MCMV K181 strain comprising a tracing elements expression cassette and a BAC backbone, wherein the BAC backbone and the tracing elements expression cassette are inserted together between M06 open reading frame and M07 open reading frame of K181 strain genome; wherein the tracing elements expression cassette comprises three tracing elements coding sequences; and wherein the tracing elements expression cassette from 5′ to 3′ sequentially comprises a first fluorescent protein, a first linker, a second fluorescent protein, a second linker, a luciferase and a polyA.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
ARENA REPLICA DEFECTIVE VARIANT
The invention relates to an infectious arenavirus particle that is genetically engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but incapable of producing further infectious progeny particles in normal, non-genetically engineered cells.One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z, and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells, but still allow gene expression in arenavirus vector-infected cells, and foreign genes encoding an antigen or other protein of interest or nucleic acids that regulate host gene expression are expressed under the control of arenavirus promoters, internal ribosome entry sites, or under the control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II, or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.
Owner:UNIVERSITY OF ZURICH
Sequence optimization method for improving stability of circular RNA, application and product
The invention discloses a sequence optimization method for improving the stability of circular RNA, application and a product, and belongs to the technical field of biotechnology and molecular biology. In order to solve the problem that the existing circular RNA is easy to be specifically degraded by RNAseK and lysosome after entering a cell, synonymous mutation optimization is carried out on an open reading frame of a target gene of the circular RNA by identifying nucleic acid motifs (a first type of nucleic acid motifs and a second type of nucleic acid motifs) identified by two degradation mechanisms. The optimized circular RNA is prepared by means of in-vitro cyclization of an anabaena I-type intron self-splicing mediator, after cells are transfected, the intracellular RNA expression level of the circular RNA is remarkably improved compared with that of a wild type, and the target protein expression efficiency is also remarkably improved. The intracellular stability and expression efficiency of the circular RNA are remarkably enhanced, and the method can be widely applied to the scenes of gene expression regulation, protein synthesis, gene therapy, vaccine development and the like.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT +1
Engineered polynucleotides for cell selective expression
The disclosure features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule, optionally a second polynucleotide encoding an effector, repressor, or endonuclease molecule; optionally a recognition or cleavage site in the first or second polynucleotide, and optionally a repressor / effector binding site in the first polynucleotide. The disclosure also features compositions or systems and uses thereof, comprising a messenger RNA (mRNA) comprising (i) an open reading frame encoding a polypeptide, and (ii) at least six miR142 target sites.
Owner:MODERNATX INC
Rice adiponectin receptor ospls3 protein and coding gene and application thereof
The application discloses a rice anti-Rhizoctonia solani leptin receptor OsPLS3 protein and an encoding protein and application thereof. The rice leptin receptor OsPLS3 protein has an amino acid sequence as shown in SEQ ID NO. 3. A coding gene of the rice leptin receptor gene OsPLS3 has a genomic nucleotide sequence as shown in SEQ ID NO. 1, and an open reading frame nucleotide sequence of the rice leptin receptor gene OsPLS3 is as shown in SEQ ID NO. 2. Experiments prove that overexpression of the rice leptin receptor gene OsPLS3 in the application in rice can improve the resistance of the rice to the Rhizoctonia solani, and the rice is more susceptible to the Rhizoctonia solani after knockout, namely, the OsPLS3 positively regulates the resistance of the rice to the Rhizoctonia solani. The rice leptin receptor gene OsPLS3 has important production value for breeding of the rice resistant to the Rhizoctonia solani.
Owner:CHINA AGRI UNIV
Plasmid of bacillus, artificial recombinant vector as well as construction method and application of plasmid and artificial recombinant vector
The invention belongs to the technical field of gene engineering, and relates to a plasmid of bacillus, an artificial recombinant vector as well as a construction method and application thereof, the plasmid is called pBso for short, and the nucleotide sequence of the plasmid is shown as SEQ ID NO.1. In a plasmid sequence, a protein coded by an open reading frame is a replication element Rep protein of a gram-positive bacterium rolling circle replication type plasmid, and the nucleotide sequence of the protein is shown as SEQ ID NO.2. The artificial recombinant vector is constructed by carrying out gene recombination on plasmids of the bacillus. The construction method of the artificial recombinant vector comprises the following steps: cloning a replication element Rep protein by using a molecular cloning means to construct the artificial recombinant vector with neomycin resistance. The replication element Rep protein of the plasmid pBso of the bacillus can be used for constructing an artificial recombinant vector, stably exists in the bacillus subtilis and the bacillus amyloliquefaciens and is subjected to replication and passage, and the steps of obtaining the engineering bacillus are simplified.
Owner:ZHEJIANG HUAKANG PHARMA
Artificial nucleic acid molecule
The present invention relates to artificial nucleic acid molecules comprising at least one open reading frame and at least one 3'-untranslated region element (3'-UTR element) and / or at least one 5'-untranslated region element (5'-UTR element), wherein said artificial nucleic acid molecule is characterized by a high translation efficiency. Said translation efficiency is at least partially due to said 5'-UTR element or said 3'-UTR element, or due to both said 5'-UTR element and said 3'-UTR element. The present invention further relates to the use of said artificial nucleic acid molecules in gene therapy and / or gene vaccination. Furthermore, novel 3'-UTR elements and 5'-UTR elements are provided.
Owner:CUREVAC SE
Helper constructs that enable rapid regeneration in cotton and methods of using the same
This invention relates to polynucleotides comprising a LEAFY COTYLEDON 1 (LEC1A) open reading frame in antisense orientation and expression cassettes, vectors, and compositions comprising the same for the purpose of enabling rapid somatic regeneration in a nonembryonic cell, as well as methods of making and methods of using the same.
Owner:CLEMSON UNIV RES FOUND
Application of soybean GmDsPTP12 gene in regulation and control of aluminum toxicity stress tolerance of plants
The invention discloses application of a soybean GmDsPTP12 gene in regulation and control of aluminum toxicity stress tolerance of plants, a nucleotide sequence of a CDS open reading frame of the GmDsPTP12 gene is as shown in SEQ ID NO: 1, and an amino acid sequence of a protein coded by the GmDsPTP12 gene is as shown in SEQ ID NO: 2. It is found that the soybean GmDsPTP12 gene can regulate and control the aluminum toxicity tolerance of soybeans, the aluminum toxicity tolerance of the soybeans is enhanced by overexpressing the soybean GmDsPTP12 gene, and the aluminum toxicity tolerance of the soybeans can be reduced by knocking out or interfering the expression of the soybean GmDsPTP12 gene.
Owner:INST OF NANFAN& SEED IND GUANGDONG ACAD OF SCI +1
Modulation of SPP1 gene and OPN protein expression, methods and applications thereof
An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.
Owner:PAINE THERAPEUTICS INC +1